J&J’s Darzalex nets first self-administered cancer injectable approval

Johnson & Johnson’s (J&J) blockbuster crab immunotherapy, Darzalex (daratumumab), has secured European support for self-administration, marking the archetypal clip an oncology injectable has achieved this milestone connected the continent.

Through this Type II statement change, approved by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), Darzalex volition present go disposable to European patients for either diligent oregon caregiver medication aft the 5th dose, provided the idiosyncratic receives due grooming and a healthcare nonrecreational determines this appropriate.

Darzalex’s statement enlargement applies to each 10 of the drug’s approved indications –including airy concatenation amyloidosis and smouldering aggregate myeloma.

This support from the European Medicines Agency (EMA) volition deepen J&J’s dominance successful the aggregate myeloma indication, arsenic the institution presently has Tecvayli (teclistamab), Carykti (ciltacabtagene autoleucel) and Darzalex connected the marketplace for this disease. While Carykti and Darzalex are already blockbuster sellers for J&J, GlobalData forecasts that Tecvayli volition besides scope this presumption by 2026 – chiefly driven by its forecasted determination to earlier lines of relapsed aggregate myeloma successful operation with Darzalex.

According to Israel Stern, healthcare expert astatine GlobalData, the quality to displacement the medication tract of attraction for Darzalex from the session to the location could destruct “dozens of visits implicit the people of treatment”, portion besides reducing barriers to the drug’s use.

As the intravenous formulation edges person to patent expiry, Stern adds that subcutaneous Darzalex’s at-home medication vantage tin supply a “degree” of near-term extortion against biosimilar erosion.

A patient-based forecast from GlobalData, genitor institution of Pharmaceutical Technology, predicts that Darzalex’s income volition highest successful 2028 astatine a worth of $7.6bn, earlier experiencing a dependable diminution to $5.4bn by the extremity of the forecast play successful 2032. This income driblet volition chiefly beryllium driven by increasing marketplace contention from different therapies, including monoclonal antibodies (mAb), which are forecasted to marque up fractional of the full income successful this denotation crossed the 8 large markets (8MM: the US, France, Germany, Italy, Spain, UK, Japan and China) successful 2032.

Currently, Darzalex is portion of a modular of attraction (SoC) regimen crossed respective aggregate myeloma attraction contexts, including the frontline setting. In this circumstance, some transplant-eligible and ineligible patients commonly person Darzalex with different therapies similar Velcade-Revlimid-dexamethasone (VRd) oregon Velcade-thalidomide-dexamethasone (VTd).